1,721,021 research outputs found
quantitative molecular detection of IgH rearrangement in multiple myeloma: comparison of two innovative techniques
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
BORTEZOMIB IS ABLE TO INACTIVATE NF-KB AND DOWN-REGULATE WT1 GENE IN P39 CELL LINE: A POSSIBLE USE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES?
No full textVASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) POLYMORPHISMS AND THEIR RELATIONSHIP WITH CLINICAL OUTCOME OF MANTLE CELL LYMPHOMA
No full textBORTEZOMIB COMBINED WITH HISTONE DEACETYLASE INHIBITOR ITF2357 OR ARSENIC TRIOXIDE EXERTS SYNERGISTIC ANTI-PROLIF- ERATIVE AND PRO-APOPTOTIC EFFECTS IN P39 CELL LINE: A POSSI- BLE NEW APPROACH TO HIGH-RISK MYELODYSPLASTIC SYNDROMES
No full textSignificant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis
No full textA high expression of Wilms tumor gene (WT1) in acute
myeloid leukemia (AML) seems to correlate with a poor outcome and its
increased levels can be predictive of an impending relapse. WT1 has been
shown in vitro to interact with the promoter of the MDR1, a gene
involved in the multidrug resistance phenomenon. The aim of this study
was to measure, by real-time polymerase chain reaction, levels of WT1
and MDR1 expression, in order to find a possible association between
these genes, in a series of 50 newly diagnosed AML cases. Twenty-five
percent of patients carried very high (>75 percentile) MDR1- and
23.3% WT1-mRNA levels. Interestingly, high levels of WT1 were
significantly correlated with correspondent high levels of MDR1 gene.
Nevertheless, the co-expression of these genes did not significantly
influence the complete response rate to the induction therapy.
Reported data confirm the existence of a co-expression of WT1 and
MDR1 genes even in vivo; this may be relevant because one consequence
could be the positive selection by chemotherapeutic regimens of cells
with higher MDR1 levels already present before treatment. Thus, the
association between these genes could suggest avoiding the use of drugs
involved in the multidrug resistance (MDR) phenomenon in patients
carrying high levels of WT1 at diagnosis
HISTONE DEACETYLASE INHIBITOR ITF2357 EXERT SIGNIFICANT ANTI-PROLIFERATIVE AND PRO-APOPTOTIC EFFECTS ON THE P39 CELL LINE: A GENE EXPRESSION STUDY
No full textEvaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients
No full textExpression of two MDR genes, BCRP and MDR1, was evaluated by real-time PCR technique in 51 AML patients. Fifty-six percent expressed the BCRP gene, with the 48.2% showing intermediate levels. Eighty-eight percent expressed the MDR1, with 23.8% of cases at high expression. A significant correlation between BCRP and MDR1 values was found by regression analysis. Either levels of BCRP or MDR1 did not correlate with clinical characteristics of patients at diagnosis
- …
